Literature DB >> 6239898

C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.

L F Fries, T A Gaither, C H Hammer, M M Frank.   

Abstract

We have prepared C3b covalently linked to IgG via a hydroxylamine-sensitive bond between the C3b alpha' chain and sites predominantly, but not exclusively, located in the IgG heavy chain. This C3b species displays relative resistance to inactivation by factors H and I when compared with free C3b. This resistance appears to be due entirely to reduced affinity of C3b-IgG for factor H. Resistance to inactivation is not conferred on C3b by binding to another serum glycoprotein of similar size, ceruloplasmin, and may be a special property of IgG. C3b-IgG demonstrates an enhanced capacity to consume serum C3 relative to C3b. These alterations of the behavior of C3b when bound to IgG may in part explain the augmentation of alternative pathway activity by IgG. In addition, IgG-induced protection of C3b might influence both complement-mediated killing and phagocytosis of bacteria, as well as modify the in vivo handling of IgG-containing soluble immune complexes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6239898      PMCID: PMC2187521          DOI: 10.1084/jem.160.6.1640

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

1.  Demonstration of circulating immune complexes in Sjögren's syndrome.

Authors:  T J Lawley; H M Moutsopoulos; S I Katz; A N Theofilopoulos; T M Chused; M M Frank
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

2.  Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.

Authors:  M D Kazatchkine; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

3.  The physiological breakdown of the third component of human complement.

Authors:  R A Harrison; P J Lachmann
Journal:  Mol Immunol       Date:  1980-01       Impact factor: 4.407

4.  The binding of activated C3 to polysaccharides and immunoglobulins.

Authors:  P J Capel; O Groeneboer; G Grosveld; K W Pondman
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

5.  Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.

Authors:  Y Takata; N Tamura; T Fujita
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

6.  Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA).

Authors:  T A Gaither; C H Hammer; M M Frank
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

7.  Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte.

Authors:  D T Fearon
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

8.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

9.  The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.

Authors:  M S Edwards; A Nicholson-Weller; C J Baker; D L Kasper
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  42 in total

1.  Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.

Authors:  E Jelezarova; A Vogt; H U Lutz
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood.

Authors:  Hanmant Gaikwad; Yue Li; Geoffrey Gifford; Ernest Groman; Nirmal K Banda; Laura Saba; Robert Scheinman; Guankui Wang; Dmitri Simberg
Journal:  Bioconjug Chem       Date:  2020-06-29       Impact factor: 4.774

3.  Influence of serotype of group B streptococci on C3 degradation.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 4.  Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation.

Authors:  Hans U Lutz; Peter J Späth
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

5.  Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.

Authors:  G A Jarvis; N A Vedros
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

6.  Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.

Authors:  H Shoham-Kessary; Y Naot; H Gershon
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

7.  Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa.

Authors:  N L Schiller; K A Joiner
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

8.  Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation.

Authors:  J C Magee; B H Collins; R C Harland; B J Lindman; R R Bollinger; M M Frank; J L Platt
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Analysis of C3 deposition and degradation on Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  G A Jarvis
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.

Authors:  A P van Dam; C E Hack
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.